PPARA and metabolic dysfunction-associated steatohepatitis: Elafibranor, a dual PPAR-α/δ agonist, also studied in non-alcoholic steatohepatitis (NASH) [47], was recently tested in a multicenter, randomized, double-blind, placebo-controlled phase 2 study clinical trial recruiting patients with PBC non-responders to UDCA.